Literature DB >> 12756511

CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations.

C Balram1, Qingyu Zhou, Yin Bun Cheung, Edmund J D Lee.   

Abstract

OBJECTIVE: To determine the frequencies of two functional single nucleotide polymorphisms, CYP3A5*3 and CYP3A5*6, in the CYP3A5 gene in three distinct Asian ethnic groups, namely, the Chinese, Malays and Indians.
METHODS: Single nucleotide polymorphism analyses of CYP3A5*1, *3 and *6 were performed in 296 healthy subjects (108 Chinese, 98 Malays and 90 Indians) using the polymerase chain reaction-restriction fragment length polymorphism method.
RESULTS: The *1 allele frequency was 25% in Chinese compared with 40% in Malays and Indians ( P=0.001). The *3 allele frequency was also higher in the Chinese population, being 76% versus 60% in the Malays and Indians ( P=0.001). The Malays and Indians also had allele frequencies significantly different from Caucasian, Japanese and African-American populations (each P<or=0.001) previously published in the literature. The *6 allele was not detected in any the three Asian ethnic groups analysed.
CONCLUSION: These results seem to suggest that genetic polymorphisms in CYP3A5 in Asians, in particular Malays and Indians but also Chinese although to a lesser extent, may be an important genetic contributor to interindividual as well as interethnic differences in clearance of CYP3A substrates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12756511     DOI: 10.1007/s00228-003-0594-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population.

Authors:  Shuichi Fukuen; Tsuyoshi Fukuda; Hiromi Maune; Yuka Ikenaga; Isamu Yamamoto; Tadanobu Inaba; Junichi Azuma
Journal:  Pharmacogenetics       Date:  2002-06

3.  The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.

Authors:  J Hirth; P B Watkins; M Strawderman; A Schott; R Bruno; L H Baker
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

4.  The genetic determinants of the CYP3A5 polymorphism.

Authors:  E Hustert; M Haberl; O Burk; R Wolbold; Y Q He; K Klein; A C Nuessler; P Neuhaus; J Klattig; R Eiselt; I Koch; A Zibat; J Brockmöller; J R Halpert; U M Zanger; L Wojnowski
Journal:  Pharmacogenetics       Date:  2001-12

Review 5.  Cytochrome P450 and the individuality of species.

Authors:  D R Nelson
Journal:  Arch Biochem Biophys       Date:  1999-09-01       Impact factor: 4.013

6.  Expression and localization of CYP3A4 and CYP3A5 in human lung.

Authors:  S Anttila; J Hukkanen; J Hakkola; T Stjernvall; P Beaune; R J Edwards; A R Boobis; O Pelkonen; H Raunio
Journal:  Am J Respir Cell Mol Biol       Date:  1997-03       Impact factor: 6.914

7.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

Authors:  T Shimada; H Yamazaki; M Mimura; Y Inui; F P Guengerich
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

Review 8.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

Authors:  D R Nelson; L Koymans; T Kamataki; J J Stegeman; R Feyereisen; D J Waxman; M R Waterman; O Gotoh; M J Coon; R W Estabrook; I C Gunsalus; D W Nebert
Journal:  Pharmacogenetics       Date:  1996-02

9.  Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients.

Authors:  Balram Chowbay; Sivathasan Cumaraswamy; Yin Bun Cheung; Qingyu Zhou; Edmund J D Lee
Journal:  Pharmacogenetics       Date:  2003-02

10.  Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver.

Authors:  J D Schuetz; D L Beach; P S Guzelian
Journal:  Pharmacogenetics       Date:  1994-02
View more
  27 in total

1.  Mapping genes that predict treatment outcome in admixed populations.

Authors:  T M Baye; R A Wilke
Journal:  Pharmacogenomics J       Date:  2010-10-05       Impact factor: 3.550

2.  PharmGKB summary: very important pharmacogene information for CYP3A5.

Authors:  Jatinder Lamba; Joan M Hebert; Erin G Schuetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

3.  Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Authors:  Al-Motassem Yousef; Nailya R Bulatova; William Newman; Nancy Hakooz; Said Ismail; Hisham Qusa; Farah Zahran; Nidaa Anwar Ababneh; Farah Hasan; Imad Zaloom; Ghada Khayat; Rawan Al-Zmili; Randa Naffa; Ola Al-Diab
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

4.  Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.

Authors:  Khemjira Yaowakulpatana; Somratai Vadcharavivad; Atiporn Ingsathit; Nutthada Areepium; Surasak Kantachuvesiri; Bunyong Phakdeekitcharoen; Chonlaphat Sukasem; Supasil Sra-Ium; Vasant Sumethkul; Chagriya Kitiyakara
Journal:  Eur J Clin Pharmacol       Date:  2015-12-04       Impact factor: 2.953

5.  Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.

Authors:  Jung-Won Suh; Bon-Kwon Koo; Shu-Ying Zhang; Kyung-Woo Park; Joo-Youn Cho; In-Jin Jang; Dong-Soon Lee; Dae-Won Sohn; Myoung-Mook Lee; Hyo-Soo Kim
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

Review 6.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

8.  Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.

Authors:  Joanne S L Lim; Xiang A Chen; Onkar Singh; Yoon S Yap; Raymond C H Ng; Nan S Wong; Mabel Wong; Edmund J D Lee; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

9.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

10.  Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.

Authors:  Hee-Doo Yoo; Hea-Young Cho; Yong-Bok Lee
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.